anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background: Many health professionals report feeling uncomfortable talking with patients who hear voices. Patients who hear voices report feeling a lack of support and empathy from emergency nurses. A local emergency department reported a need for training for nurses in the care of behavioral health patients. Objective: The aim of this study is to implement a quality improvement project using a hearing voices simulation. Empathy was measured using the Toronto Empathy Questionnaire, and a post-intervention survey was used to evaluate emergency nurses' perception of the professional development session. Methods: The quality improvement project included the implementation of a hearing voices simulation with emergency nurses. A paired t-test was used to determine the differences in the nurses empathy levels pre-and post-simulation. Qualitative data was collected on the nurses' experience during the simulation debriefing. A Likert-style questionnaire was used to collect data on the nurses' evaluation of the simulation. Results: The results of the hearing voices simulation were a statistically significant increase (p < .00) in empathy from baseline (M = 47.95, SD = 6.55) to post-intervention empathy scores (M = 48.93, SD = 6.89). The results of the post-simulation survey indicated that nurses felt that the hearing voices simulation was useful (n = 100; 98%) and helped them to feel more empathetic toward patients who hear voices (n = 98; 96%). Conclusions: Using a hearing voices simulation may help emergency nurses feel more empathetic toward the behavioral health patients who hear voices. Implications for Nursing: Through the implementation of a hearing voices simulation, clinical staff educators can provide support to staff nurses in the care of behavioral health patients.
BACKGROUND: This study aimed to analyze the associations of cardiometabolic index (CMI) with diabetic statuses and insulin resistance (IR) using data from the National Health and Nutrition Examination Survey (NHANES) and examined the potential mediating role of inflammation in these correlations.
METHODS: This study enrolled 9477 participants across four NHANES cycles from 2011 to 2018. The primary outcomes of the study included the risk of having prediabetes, diabetes and the level of the homeostasis model assessment of IR (HOMA-IR). Other outcomes including the levels of fasting blood glucose (FBG), hemoglobin A1c (HbA1c), oral glucose tolerance test (OGTT) results, fasting insulin, the risk of oral hypoglycemic medicine use, insulin use, and retinopathy were also collected and analyzed. Logistic regression model, subgroup analysis, restricted cubic spine (RCS), and Pearson correlation coefficients were conducted to assess the associations of CMI with diabetic statuses and IR. The mediating role of inflammation was evaluated to investigate the potential mechanism of the associations between CMI and diabetic statuses.
RESULTS: Among included participants, the CMI levels in normal participants, prediabetes and diabetes in this study were 0.48, 0.73 and 1.07. After multivariable adjustment, CMI was positively associated with the risk of prediabetes (OR = 1.49, 95% CI = 1.24-1.79), diabetes (OR = 2.14, 95% CI = 1.82-2.50) and the level of HOMA-IR (β = 2.57, 95% CI = 2.14-3.01). Besides, an increased CMI was correlated with higher levels of FBG, HBA1c, OGTT results and fasting insulin as well as the greater risk of oral hypoglycemic medicine use and insulin use. The RCS showed an inverted L-shaped association of CMI with prediabetes and diabetes (P for non-linearity < 0.001). According to Pearson correlation coefficients, higher CMI was linked to higher rises in HOMA-IR (r = 0.224, P < 0.001). Inflammation-related indicators including leukocyte and neutrophil demonstrated significant mediating effects in the associations of CMI with prediabetes (15.5%, 9.8%), diabetes (5.1%, 6.0%) and HOMA-IR (3.3%, 2.6%).
CONCLUSION: CMI was positively associated with the risk of worse diabetic statuses and higher level of IR while the associations may be partially mediated by inflammation-related indicators, suggesting that CMI could be a promising indicator for the prediction of severe diabetes and IR.
OBJECTIVE: The aim of this study was to evaluate the outcomes of cold stored saphenous vein allografts (CSVAs) for haemodialysis vascular access.
METHODS: A retrospective, two centre study was conducted between January 2016 and December 2020 of all patients who had CSVA placement for haemodialysis vascular access. Primary, primary assisted, and secondary patency were analysed, as well as procedural complications and re-interventions.
RESULTS: One hundred and nine patients (n = 55 women) with a mean age of 67.2 ± 13.6 years, with no options for creating an autogenous arteriovenous fistula, were included in the study. At one year, primary, primary assisted, and secondary patency were 37.6%, 59.0%, and 73.3%, respectively; and at two years 19.9%, 42.5%, and 54.9%, respectively. During a mean follow up period of 26 ± 18 months, five patients (4.6%) had an access infection, with no related death. During the follow up period, 32 patients (29.4%) died and 13 patients (11.9%) underwent a kidney transplant. None of these patients showed immunoconversion before transplantation. The cumulative incidence of adverse events by the Fine-Gray method was calculated. Considering competing risks (death and renal transplantation), 9.2% of patients lost their vascular access at one year and 18% at two years. Moreover, 57.8% patients had stenosis, mainly on the outflow (45.9%), and 49.5% had thrombosis.
CONCLUSION: With a comparable patency rate associated with a low infection rate, CSVA offers a potential alternative to expanded polytetrafluoroethylene grafts. This creates haemodialysis vascular access when the venous capital is exhausted in patients with reported risk factors for vascular access infection, i.e., insertion in the thigh, advanced age, diabetes mellitus, immunocompromised state, obesity, or revision of an infected prosthetic graft.
Composition for dyeing of keratinous fibers comprises an oxidation base comprising 2,3-diamino-6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazol-1-one (I) and its salts, a coupler, a surfactant comprising oxyalkylenated or glycerolated fatty alcohols, anionic surfactants comprising sulfate or sulfonate and amphoteric surfactants comprising betaine and an oxidizing agent in a medium. The pH of the composition is 5.5-7.5. Composition for dyeing of keratinous fibers comprises an oxidation base comprising 2,3-diamino-6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazol-1-one of formula (I) and its salts, a coupler, a surfactant comprising oxyalkylenated or glycerolated fatty alcohols, anionic surfactants comprising sulfate or sulfonate and amphoteric surfactants comprising betaine and an oxidizing agent in a medium, provided that when the composition comprises oxyalkylenated or glycerolated fatty alcohols, it is free from 3-amino 2-methylamino-6-methoxy pyridine, cationic polyurethane with fatty chain obtained from the condensation of quaternized 1,3-bis-(isocyanatomethylcyclohexane)-N,N-dimethylethanolamine with bromodecane N,N-dimethylethanolamine and polyoxyethylene, polycondensate of polyethylene glycol with 150-180 moles ethylene oxide, decylic alcohol and methylene-bis (4-cyclohexylisocyanate), mixture of polyglycerolated cetearylic alcohol with 2 moles of glycerol and polyglycerolated cetearylic alcohol with 6 moles of glycerol and hexyleneglycol. The pH of the composition is 5.5-7.5. Independent claims are included for: (1) dyeing of keratinous fibers comprising application of the dyeing composition on the keratinous fibers and rinsing, optionally washing with shampoo, rinsing again and drying; and (2) a device with compartments comprising a first compartment containing a composition (A1) comprising an oxidation base comprising (I), a coupler and a surfactant in a medium and a composition (A2) comprising an oxidizing agent in a medium. [Image].
Lyme disease is the most commonly reported arthropod-borne infection in the US with recent CDC estimates eclipsing 300,000 new cases in 2013. In addition to growing in frequency, the infections have a complex and increasingly severe course. Beginning with mild flu-like symptoms and frequently a signature bull's-eye rash, erythema migrans, Lyme disease can progress to severe articular, neurological and cardiac symptoms, most of which are preventable with early antibiotic therapy. Leading investigators have identified two major shortcomings to the current serology-based methods for the definitive diagnosis of Early Localized Lyme disease. First, the clinical sensitivity in the first four weeks is poor, under 50% at the time of symptom onset, so many patients remain undiagnosed or unconfirmed until the disease has had time to progress. Second, serum antibody levels remain elevated long after the infection has been resolved making the monitoring of therapeutic success or diagnosis of re-infection virtually impossible. MicroB-plex will address these shortcomings by using a novel sample matrix from circulating antibody secreting cells (ASC) for diagnosis of Lyme disease. This novel matrix is MENSA (medium enriched for newly synthesized antibody). In this study, MicroB-plex and its clinical collaborators will test whether MENSA is effective in early Lyme diagnostic (within the first 2 weeks) and if this new approach will track therapeutic success.
New vaccine for birds is avian blood contg. immune factors against viruses, bacteria, protozoa, nematodes, trematodes and/or fungal infections. The vaccine is pref. in the form of defibrinated blood contg. immune factors, or of immune-factor-contg. avian blood which has been treated with agent which inhibit coagulation of blood by fibrinogen. The new vaccine permits a single immunization to be used to afford protection against a wide range of organisms, including nematodes and trematodes. In none of over 2500 birds treated with the vaccine has there been any adverse effect.
A system and method for predicting loss associated with a patient's use of a treatment device is disclosed. The communication interface collects event data related to the operation of the treatment device to deliver medication to the patient. Event data and clinical data of the patient are stored. The attrition analysis module inputs the event data and the clinical data and applies a machine learning model to determine a likelihood of attrition of the patient over a predetermined period of time based on the input event data and clinical data. The machine learning model is trained from a machine learning pipeline having event data and clinical data from a patient population using a treatment apparatus as inputs to determine at least one trigger for patient churn. It is determined whether the likelihood of churn exceeds a threshold. If the likelihood of loss exceeds a threshold, an action associated with the patient is triggered.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to urology. After the implementation of retropubic access to the prostate, carbon dioxide is insufflated into the retropubic space. Then, using a puncture needle, the anterior abdominal wall is punctured in the area of ​​the pubic articulation through all layers of tissue. After visualization of the needle tip in the operating space, the tissues are punctured in the region of the dorsal complex of the prostate gland to the right of the urethra and 2.5 ml of the prepared remestip solution is injected, namely, up to 10 ml of 0.9% saline solution is added to 0.4 mg of the remestip. Then another 2.5 ml of solution is injected symmetrically to the left of the urethra, then 2.5 ml of the solution is injected into the region of the neurovascular bundles of the prostate on the right and left, and the puncture needle is removed. After 3-5 minutes, a cross-section of the anterior surface of the prostate capsule is made 1.5-2 cm below the proximal to the puboprostatic ligaments, 5-7 cm long. A layer is isolated between the capsule and the adenomatous tissue of the right and left lobes of the prostate gland. Then, bluntly and using the THUNDERBEAT apparatus, the adenomatous nodes are cut off. The prostatic part of the urethra is cut off, then small vessels are coagulated by bipolar coagulation, the adenomatous nodes are immersed in a container, after removal of the adenomatous tissues, the posterior wall of the bladder with the urethra is fixed proximally by 1 cm of the vas deferens with a continuous V-Loc thread with a length of 15 cm with a 5/8 cm needle , produce "trigonization" of the posterior wall of the bladder, followed by puncture of the needle on the anterior surface of the upper leaf of the prostate capsule and suturing along the right semicircle of the capsule of the prostate gland with the capture of the wall of the urinary bladder along the lateral, with the transition to the anterior surface, suturing the tissues on the left side symmetrically; the tightness of the anastomosis is controled. Then the container is removed. A tubular drainage is installed in the retropubic space. Sutures are applied to the skin, iodine treatment and an aseptic bandage are applied.EFFECT: method allows to reduce the volume of the patient's surgical blood loss associated with profuse bleeding from the prostate tissue as a result of dissection of the surgical capsule.1 cl, 1 ex, 2 tbl
Hemostatic materials are of great significance for rapid control of bleeding, especially in military trauma and traffic accidents. Chitosan (CS) hemostatic sponges have been widely concerned and studied due to their excellent biocompatibility. However, the hemostatic performance of pure chitosan sponges is poor due to the shortcoming of strong rigidity. In this study, CS and hydroxypropylmethylcellulose (HPMC) were combined to develop a safe and effective hemostatic composite sponges (CS/HPMC) for hemorrhage control by a simple mixed-lyophilization strategy. The CS/HPMC exhibited excellent flexibility (the flexibility was 74% higher than that of pure CS sponges). Due to the high porosity and procoagulant chemical structure of the CS/HPMC, it exhibited rapid hemostatic ability in vitro (BCI was shortened by 50% than that of pure CS sponges). The good biocompatibility of the obtained CS/HPMC was confirmed via cytotoxicity, hemocompatibility and skin irritation tests. The CS/HPMC can induced the erythrocyte and platelets adhesion, resulting in significant coagulation acceleration. The CS/HPMC had excellent performance in vivo assessments with shortest clotting time (40 s) and minimal blood loss (166 mg). All above results proved that the CS/HPMC had great potential to be a safe and rapid hemostatic material.
The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
Patients receive pazopanib hydrochloride PO QD on days 1-28 and ascorbic acid IV three times per week. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
The present invention provides a method for populating and searching a drug informatics database that includes receiving unprocessed data associated with a chemical compound from one or more data sources. The unprocessed data is parsed into a plurality of data objects based on a categorization associated with each of the data objects. Additional information, such as explanatory notes, is identified and associated with at least one of the data objects. The data objects are stored in entries within a data structure, where the data structure is searchable based on one or more of the data objects. A query for data associated with a chemical compound is received at a drug informatics database. The drug informatics database is then searched for data associated with the chemical compound and the search results are provided to a user.
Brucella is an intracellular parasitic bacterium lacking typical virulence factors, and its pathogenicity primarily relies on replication within host cells. In this study, we observed a significant increase in spleen weight in mice immunized with a Brucella strain deleted of the gene for alanine racemase (Alr), the enzyme responsible for alanine racemization (Δalr). However, the bacterial load in the spleen markedly decreased in the mutant strain. Concurrently, the ratio of white pulp to red pulp in the spleen was increased, serum IgG levels were elevated, but no significant damage to other organs was observed. In addition, the inflammatory response was potentiated and the NF-κB-NLRP3 signaling pathway was activated in macrophages (RAW264.7 Cells and Bone Marrow-Derived Cells) infect ed with the Δalr mutant. Further investigation revealed that the Δalr mutant released substantial amounts of protein in a simulated intracellular environment which resulted in heightened inflammation and activation of the TLR4-NF-κB-NLRP3 pathway in macrophages. The consequent cytoplasmic exocytosis reduced intracellular Brucella survival. In summary, cytoplasmic exocytosis products resulting from infection with a Brucella strain deleted of the alr gene effectively activated the TLR4-NFκB-NLRP3 pathway, triggered a robust inflammatory response, and reduced bacterial survival within host cells. Moreover, the Δalr strain exhibits lower toxicity and stronger immunogenicity in mice.
This trial evaluates the feasibility, acceptability, and preliminary efficacy of telephone-based Acceptance and Commitment Therapy (ACT) on fatigue interference in advanced gastrointestinal (GI) cancer patients and family caregiver burden as well as secondary outcomes. The study team recruited advanced GI cancer patients receiving care at the Indiana University Simon Cancer Center or Eskenazi Health hospital. Potentially eligible patients were mailed an introductory letter signed by their oncologist and the PI along with a consent form. The letter had a number to call if they did not wish to be contacted further. A research assistant (RA) called all prospective participants who did not opt out approximately 1 to 2 weeks after the letter was mailed. The RA described the study as outlined in the consent form and answered any questions. Then the RA administered an eligibility screening to those who consented to participate. Eligible and consenting patients identified a potentially eligible family caregiver. If the family caregiver was eligible and consented to participate, then the patient and caregiver each completed a baseline phone assessment. Following baseline assessments, patient-caregiver dyads (N = 40 dyads) were randomly assigned in equal numbers to ACT or education/support using a stratified block randomization scheme to balance the groups by patient performance status (patient-reported Eastern Cooperative Oncology Group \[ECOG\] scores 0 or 1 vs. 2). Dyads in both study conditions completed six weekly 50-minute telephone sessions with the first session occurring one week after baseline. For ACT participants, adherence to home practice during the past week was assessed and recorded during each session. Feasibility will be examined via accrual, attrition, and adherence rates, and acceptability will be evaluated using a mixed methods approach (qualitative and quantitative). Blind interviewers assessed outcomes during follow-up phone assessments at 2 weeks and 3 months post-intervention.
Stress has long been associated with substance misuse and substance use disorders (SUDs). The past two decades have seen a surge in research aimed at understanding the underlying mechanisms driving this association. This Review introduces a multilevel "adaptive stress response" framework, encompassing a stress baseline, acute reaction, and recovery with return-to-homeostasis phase that occurs at varying response times and across domains of analysis. It also discusses evidence showing the disruption of this adaptive stress response in the context of chronic and repeated stressors, trauma, adverse social and drug-related environments, as well as with acute and chronic drug misuse and with drug withdrawal and abstinence sequelae. Subjective, cognitive, peripheral, and neurobiological disruptions in the adaptive stress response phases and their link to inflexible, maladaptive coping; increased craving; relapse risk; and maintenance of drug intake are also presented. Finally, the prevention and treatment implications of targeting this "stress pathophysiology of addiction" are discussed, along with specific aspects that may be targeted in intervention development to rescue stress-related alterations in drug motivation and to improve SUD treatment outcomes.
The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The needle will be directed to the most sensitive point and advanced until it will be reached the trigger point.
Sparsentan will be administered once daily, starting at a dose of 200 mg (two 100 mg oral capsules) for the first 2 weeks of the study. Patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400 mg (one 400 mg tablet). Patients who do not tolerate the target dose will have their dose reduced back to 200 or 100 mg/day; throughout the study, patients will be maintained on the maximum allowed dose of sparsentan they can tolerate. All patients will be treated with sparsentan for a total of 110 weeks.
Sepsis-induced acute lung injury (ALI), characterized by severe hypoxemia and pulmonary leakage, remains a leading cause of mortality in intensive care units. The exacerbation of ALI during sepsis is largely attributed to uncontrolled inflammatory responses and endothelial dysfunction. Emerging evidence suggests an important role of Z-DNA binding protein 1 (ZBP1) as a sensor in innate immune to drive inflammatory signaling and cell death during infections. However, the role of ZBP1 in sepsis-induced ALI has yet to be defined. We utilized ZBP1 knockout mice and combined single-cell RNA sequencing with experimental validation to investigate ZBP1's roles in the regulation of macrophages and lung endothelial cells during sepsis. We demonstrate that in sepsis, ZBP1 deficiency in macrophages reduces mitochondrial damage and inhibits glycolysis, thereby altering the metabolic status of macrophages. Consequently, this metabolic shift leads to a reduction in the differentiation of macrophages into pro-inflammatory states and decreases macrophage pyroptosis triggered by activation of the NLRP3 inflammasome. These changes significantly weaken the inflammatory signaling pathways between macrophages and endothelial cells and alleviate endothelial dysfunction and cellular damage. These findings reveal important roles for ZBP1 in mediating multiple pathological processes involved in sepsis-induced ALI by modulating the functional states of macrophages and endothelial cells, thereby highlighting its potential as a promising therapeutic target.